ReviewCardiovascular & hematological disorders drug targets2026
Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a).
Monica Botros et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it